content top

Suprachoroidal Drug Delivery for the Treatment of Subfoveal Hard Exudates

Media not available due to technical recording problems. EVRS is very sorry for the inconvenience.   Introduction: Macular edema is one of the main causes of severe vision loss in patients with diabetic retinopathy. In the presence of hard exudates, the prognosis is frequently unfavorable. Setting: Ophthalmology Department, Hospital de Braga, Portugal. Purpose: To evaluate the safety and efïcacy of suprachoroidal drug delivery with a...

Read More

Response of Different Patterns of Diabetic Macular Edema to Treatment with a Sustained-release Dexamethasone Posterior-segment Drugdelivery System

Baruch D. Kuppermann, MD, PhD (Irvine, CA),* Connie Chou, PhD (Irvine, CA),* David V. Weinberg, MD (Milwaukee, WI),* Scott M. Whitcup, MD (Irvine, CA),* Julia A. Haller, MD (Baltimore, MD),* Mark S. Blumenkranz, MD (Stanford, CA),* George A. Williams, MD (Royal Oak, MI)* PURPOSE: To evaluate the response of different patterns of persistent diabetic macular edema (DME) unresponsive to prior medical or laser therapy to treatment with a novel...

Read More

Cannulation of the Suprachoroidal Space: Drug Delivery and Pharmacokinetics of Triamcinolone Acetonide and Bevacizumab

Timothy W. Olsen, MD (Minneapolis, MN),* Xiao Feng, MD (Minneapolis, MN),* Kathy Wabner, BA (Minneapolis, MN),* Stanley R. Conston, BS (Menlo Park, CA),* David H. Sierra, PhD (Menlo Park, CA),* Tom S. Chang, MD (Pasadena, CA),* Karl G. Csaky, MD PhD (Bethesda, MD), Morton E. Smith, MD (St. Louis, MO), J. Douglas Cameron, MD (Rochester, MN) PURPOSE: To describe a drug delivery system, surgical technique, safety and pharmacokinetics for...

Read More

Reliable and Reproducible Dosage Delivery of Triamcinolone Acetonide Prepared for Intravitreal Injection

Daniel B. Roth, MD (New Brunswick, NJ), Nancy E. Martin, PharmD, FCP (New Brunswick, NJ), Jonathan L. Prenner, MD (New Brunswick, NJ) PURPOSE: The empiric dose of 4mg in 0.1mL triamcinolone acetonide (TA) administered via intravitreal injection has demonstrated promising results for macular diseases. Variability of the actual dose delivered has been a concern with the use of Kenalog®-40 suspension. Herein, we evaluate the reproducibility...

Read More

The I-vation Sustained Release Drug Delivery System and Intravitreal Implant

Eugene de Juan, Jr., MD (San Francisco, CA),* Robert L. Avery, MD (Santa Barbara, CA), Herbert L. Cantrill, MD (Minneapolis, MN), Pravin U. Dugel, MD (Phoenix, AZ), Dean Eliott, MD (Los Angeles, CA), Charlene Anderson, (Irvine, CA)* PURPOSE: The I-Vation sustained drug delivery system was designed to provide controlled delivery of therapeutics to the back of the eye in a platform that balances minimally invasive implantation, sustained...

Read More

Three-year Results of a Multicenter Clinical Trial of the Fluocinolone Acetonide Intravitreal Implant to Treat Diabetic Macular Edema

http://www.evrs.eu/medias/2006/congress/Three-year-Results-of-a-Multicenter-Clinical-Trial-of-the-Fluocinolone-Acetonide-Intravitreal-Implant-to-Treat-Diabetic-Macular-Edema.swf Dean Eliott, MD (Los Angeles, CA),* Brian Levy, OD, MS (Rochester, NY),* Timothy L. Comstock, OD, MS (Rochester, NY)* PURPOSE: This 4-year prospective, multicenter, randomized, controlled study is being conducted to investigate the safety and  efficacy of a...

Read More
content top